AI for Biopharma

Every biopharma deck now has an AI slide. Most of them describe the same three tools and hope no one asks what actually reached a patient. The honest version is narrower and more interesting: AI is quietly reshaping the parts of drug development that were always bottlenecked by human throughput — triaging targets, reading assays, drafting the regulatory paperwork — while leaving the hard biology roughly as hard as it was.

This piece is about telling those apart: what moves a program’s timeline and cost, and what just moves a conference agenda.